
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.
Language Requirement: Fluent English (Spoken and Written is Preferred)
Preferred Experience: Pharmaceutical/Biotech Industry
Location: Sao Paulo Office
Therapeutic Areas: Oncology and Hematology
A member of BeOne Medicines' Access Team, dedicated to engaging with various internal and external stakeholders while driving reimbursement for new technologies with payers. Responsible for developing and implementing access strategies tailored to the specific needs of each stakeholder, with the goal of enhancing the patient journey, expanding access, and contributing to the sustainability of the healthcare system."
University undergraduate degree in life science or business; higher qualifications (MD, PhD, MBA) advantageous
8+ years of required relevant experience
Knowledge of the health system, processes of Incorporation of New Technologies, Health economics and of Health Technology Assessment Concepts and Tools
Supervisory Responsibilities: None
Travel: Availability to travel (20%)
Computer Skills: Standard Computer Skills required (MS Office)
Global Competencies
When we exhibit our values of Patients First, Driving Excellence, Bold Ingenuity, and Collaborative Spirit, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
We are proud to be an equal opportunity employer. BeOne does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, disability, national origin, veteran status or any other basis covered by appropriate law. All employment is decided on the basis of qualifications, merit, and business need.

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible.
To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.